Dyne Therapeutics, Inc. DYN Additional Paid-In Capital
Additional Paid-In Capital at other companies
Other financials
Where this comes from
Reported directly by Dyne Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AdditionalPaidInCapital.
The official record: Dyne Therapeutics, Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about Dyne Therapeutics, Inc.'s additional paid-in capital.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Dyne Therapeutics, Inc.'s additional paid-in capital?
- Dyne Therapeutics, Inc. (DYN) reported additional paid-in capital of $2.38B in Q1 2026.
- How has Dyne Therapeutics, Inc.'s additional paid-in capital changed year-over-year?
- Dyne Therapeutics, Inc.'s additional paid-in capital increased by 37.4% year-over-year, from $1.73B to $2.38B.
- What is the long-term trend for Dyne Therapeutics, Inc.'s additional paid-in capital?
- Over 5 years (2020 to 2025), Dyne Therapeutics, Inc.'s additional paid-in capital has grown at a 41.2% compound annual growth rate (CAGR), from $421.57M to $2.37B.
- What does additional paid-in capital mean?
- Capital received from shareholders in excess of par value — the premium investors paid over the nominal value of shares at issuance, plus stock-based compensation effects.